Showing results (291-300 of 306) with videos related to

Sort By:
Pageof 31
The Lancet. Infectious Diseases|September 10, 2022
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S Datoo, Hamtandi Magloire Natama, Athanase Somé, et al.
NPJ Vaccines|February 6, 2025
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01EM Sanni Ali, Lisa Stockdale, Issaka Sagara, et al.
The Lancet. Infectious Diseases|August 25, 2023
Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trialAlassane Dicko, Jean-Bosco Ouedraogo, Issaka Zongo, et al.
Malaria Journal|May 20, 2021
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malariaYeka Adoke, Rella Zoleko-Manego, Serge Ouoba, et al.
Plos Medicine|August 10, 2017
Malaria, malnutrition, and birthweight: A meta-analysis using individual participant dataJordan E Cates, Holger W Unger, Valerie Briand, et al.
The Lancet. Infectious Diseases|December 13, 2024
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi M Natama, Jo Salkeld, Athanase Somé, et al.
Global Health Action|September 28, 2018
Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional studyStuart A Ali, Cassandra Soo, Godfred Agongo, et al.
Vaccine|November 12, 2019
Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan AfricaLucas Otieno, Yolanda Guerra Mendoza, Samuel Adjei, et al.
The Lancet. Infectious Diseases|September 7, 2015
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialMichael T White, Robert Verity, Jamie T Griffin, et al.
Human Vaccines & Immunotherapeutics|April 24, 2019
Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan AfricaYolanda Guerra Mendoza, Elodie Garric, Amanda Leach, et al.
Pageof 31